US Patent 11040034 Metalloenzyme inhibitor compounds
Patent 11040034 was granted and assigned to Phasebio Pharmaceuticals, Inc. on June, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 12 Mar, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+176 characters)
Article
Patent abstract
Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
Edits on 10 Oct, 2023
Golden AI
Edits made to:
Infobox (+4 properties)
Infobox
Patent Inventor Names
Christopher M. Yates0
Sammy R. Shaver0
Steven Sparks0
William J. Hoekstra0
Edits on 20 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 23 Apr, 2023
Golden AI
Infobox
Patent Citations
Edits on 24 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
110400340
Date of Patent
June 22, 2021
0Patent Application Number
161248460
Date Filed
September 7, 2018
0Official Website
Patent Citations
Patent Primary Examiner
Edits on 25 Sep, 2022
Golden AI
Infobox
Patent Citations
Edits on 6 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 12 Feb, 2022
Golden AI
Edits made to:
Infobox (+10 properties)
US Patent 11040034 Metalloenzyme inhibitor compounds
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11040034
Date of patent
June 22, 2021
Patent application number
16124846
Date Filed
September 7, 2018
Patent citations
Patent primary examiner
Find more entities like US Patent 11040034 Metalloenzyme inhibitor compounds
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
